Resveratrol: An active natural compound in red wines for health

Journal of Food and Drug Analysis

Volumn 21, Issue 1, 2013, Pages

  Murtaza, Ghulam ^a   Latif, Usman ^a   Najam Ul Haq, Muhammad ^b   Sajjad, Ashif ^c   Karim, Sabiha ^d   Akhtar, Muhammad ^e   Hussain, Izhar ^a  

^a COMSATS Institute of Information Technology ^*  (Pakistan)

^b BAHAUDDIN ZAKARIYA UNIVERSITY   (Pakistan)

^c UNIVERSITY OF BALOCHISTAN   (Pakistan)

^d UNIVERSITY OF THE PUNJAB   (Pakistan)

^e THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

Author keywords

Antiaging; Anticancer; Antioxidant; Resveratrol; Wine

Indexed keywords

RESVERATROL;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; DRUG BIOAVAILABILITY; GENETIC VARIABILITY; HUMAN; RED WINE; REVIEW; TUMOR GROWTH; TUMOR PROMOTION;

EID: 84877844909     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.6227/jfda.2013210101     Document Type: Review

References (142)

1. Renaud, S. and de Lorgeril, M. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
2. Avellone, G., Di Garbo, V. and Campisi, D. et al. 2006. Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis. Eur. J. Clin. Nutr. 60: 41-47. (Pubitemid 43731073)
3. Bertelli, A. A. and Das, D. K. 2009. Grapes, wines, resveratrol, and heart health. J. Cardiovasc. Pharmacol. 54: 468-476.
4. Leighton, F., Cuevas, A. and Guasch, V. et al. 1999. Plasma polyphenols and antioxidants, oxidative DNA damage, and endothelial function in a diet and wine intervention study in humans. Drugs Exp. Clin. Res. 25: 133-141. (Pubitemid 29257606)
5. Mezzano, D., Leighton, F. and Martinez, C. et al. 2001. Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors. Eur. J. Clin. Nutr. 55: 444-451. (Pubitemid 32529936)
6. Rimm, E. B., Stampfer, M. J. and Giovannucci, E. et al. 1995. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am. J. Epidemiol. 141: 1117-1127.
7. Briggs, N. C., Levine, R. S. and Bobo, L. D. et al. 2002. Wine drinking and risk of non-Hodgkin's lymphoma among men in the United States: a population-based case-control study. Am. J. Epidemiol. 156: 454-462. (Pubitemid 34976984)
8. Platz, E. A., Leitzmann, M. F. and Rimm, E. B. et al. 2004. Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am. J. Epidemiol. 159: 444-453. (Pubitemid 38280290)
9. Schoonen, W. M., Salinas, C. A. and Kiemeney, L. A. et al. 2005. Alcohol consumption and risk of prostate cancer in middle-aged men. Int. J. Cancer 113: 133-140. (Pubitemid 39507320)
10. Schuurman, A. G., Goldbohm, R. A. and van den Brandt, P. A. 1999. A prospective cohort study on consumption of alcoholic beverages in relation to prostate cancer incidence (The Netherlands). Cancer Causes Control 10: 597-605.
11. Gammon, M. D., Schoenberg, J. B. and Ahsan, H. et al. 1997. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J. Nati. Cancer Inst. 89: 1277-1284. (Pubitemid 27371948)
12. Bessaoud, F. and Daures, J. P. 2008. Patterns of alcohol (especially wine) consumption and breast cancer risk: a case-control study among a population in Southern France. Ann. Epidemiol. 18: 467-475.
13. Sutcliffe, S., Giovannucci, E. and Leitzmann, M. F. et al. 2007. A prospective cohort study of red wine consumption and risk of prostate cancer. Int. J. Cancer 120: 1529-1535. (Pubitemid 46355389)
14. Longnecker, M. P., Orza, M. J. and Adams, M. E. et al. 1990. A meta-analysis of alcoholic beverage consumption in relation to risk of colorectal cancer. Cancer Causes Control 1: 59-68.
15. Lugasi, A. and Hovari, J. 2003. Antioxidant properties of commercial alcoholic and nonalcoholic beverages. Nahrung 47: 79-86. (Pubitemid 37373984)
16. Al-Awwadi, N. A., Bornet, A. and Azay, J. et al. 2004. Red wine polyphenols alone or in association with ethanol prevent hypertension, cardiac hypertrophy, and production of reactive oxygen species in the insulin-resistant fructose-fed rat. J. Agri. Food Chem. 52: 5593-5597.
17. Clifford, A. J., Ebeler, S. E. and Ebeler, J. D. et al. Delayed tumor onset in transgenic mice fed an amino acid-based diet supplemented with red wine solids. Am. J. Clin. Nutr. 64: 748-756.
18. Norata, G. D., Marchesi, P. and Passamonti, S. et al. 2007. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 191: 265-271. (Pubitemid 46400710)
19. Pignatelli, P., Ghiselli, A. and Buchetti, B. et al. 2006. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis 188: 77-83. (Pubitemid 44142538)
20. Kris-etherton, P. M., Hecker, K. D. and Bonanome, A. et al. 2002. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 113: S71-S88.
21. Athar, M., Back, J. H. and Tang, X. et al. 2007. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224: 274-283. (Pubitemid 47575677)
22. Shankar, S., Singh, G. and Srivastava, R. K. 2007. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potentials. Front. Biosci. 12: 4839-4854.
23. Holme, A. L. and Pervaiz, S. 2007. Resveratrol in cell fate decisions. J. Bioenerg. Biomembr. 39: 59-63. (Pubitemid 46877167)
24. King, R. E., Bomser, J. A. and Min, D. B. 2006. Bioactivity of resveratrol. Compr. Rev. Food Sci. Food Saf. 5: 65-70. (Pubitemid 44668741)
25. Das, S. and Das, D. K. 2007. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets. 6: 168-173. (Pubitemid 47455785)
26. Surh, Y. J. and Kundu, J. K. 2006. Resveratrol as an anti-inflammatory agent. In "Resveratrol in Health and Disease", pp. 601-617. Aggarwal, B. B., Shishodia, S. eds. CRC Press. Mumbay, India.
27. Signorelli, P. and Ghidoni, R. 2006. Resveratrol as an antiproliferative agent for cancer. In "Resveratrol in Health and Disease", pp. 57-83. Aggarwal, B. B., Shishodia, S. eds. CRC Press. Mumbay, India.
28. Pervaiz, S. and Holme, A. L. 2006. Mechanism of apoptosis by resveratrol. In "Resveratrol in Health and Disease", pp. 85-104. Aggarwal, B. B., Shishodia, S. eds. CRC Press. Mumbay, India.
29. Langcake, P. and Pryce, R. J. 1976. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol. 9: 77-86.
30. Siemann, E. H. and Creasy, L. L. 1992. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Vitic. 43: 49-52.
31. Carbo, N., Costelli, P. and Baccino, F. M. et al. 1999. Resveratrol, a natural product present in wine, decreases tumor growth in a rat tumor model. Biochem. Biophys. Res. Commun. 254: 739-743. (Pubitemid 29290538)
32. 14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72: 2219-2233.
33. Amri, A., Chaumeil, J. C. and Sfar, S. et al. 2012. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Control. Release 158: 182-193.
34. Wang, Y., Catana, F. and Yang, Y. et al. 2002. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J. Agric. Food Chem. 50: 431-435. (Pubitemid 34106659)
35. Yu-Jun, C., Qing-Yi, W. and Jian-Guo, F. et al. 2004. The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res. 24: 999-1002.
36. Guerrero, R. F., García-Parrilla, M. C. and Puertas, B. et al. 2009. Wine, resveratrol and health: a review. Nat. Prod. Commun. 4: 635-658.
37. Carando, S., Teissedre, P. L. and Waffo-Teguo, P. et al. 1999. High-performance liquid chromatography coupled with fluorescence detection for the determination of trans-astringin in wine. J. Chromatogr. A 849: 617-620. (Pubitemid 29320132)
38. Landrault, N., Larronde, F. and Delaunay, J. C. et al. 2002. Levels of stilbene oligomers and astilbin in French varietal wines and in grapes during noble rot development. J. Agric. Food Chem. 50: 2046-2052. (Pubitemid 34260009)
39. Romero-Pérez, A., Lamuela-Raventós, R. M. and Waterhouse, A. L. et al. 1996. Levels of cis- and trans-resveratrol and their glucosides in white rosé and Vitis vinifera wines from Spain. J. Agric. Food Chem. 44: 2124-2128. (Pubitemid 126454426)
40. Stervbo, U., Vang, O. and Bonnesen, C. 2006. Time-and concentration-dependent effects of resveratrol in HL-60 and HepG2 cells. Cell Prolif. 39: 479-493. (Pubitemid 44760200)
41. Buiarelli, F., Coccioli, F. and Jasionowska, R. et al. 2007. Analysis of some stilbenes in Italian wines by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21: 2955-2964. (Pubitemid 47401432)
42. Mercolini, L., Addolorata Saracino, M. and Bugamelli, F. et al. 2008. HPLC-F analysis of melatonin and resveratrol isomers in wine using an SPE procedure. J. Sep. Sci. 31: 1007-1014. (Pubitemid 351649826)
43. Soleas, G. J., Goldberg, D. M. and Karumanchiri, A. et al. 1995. Influences of viticultur and oenological factors on changes in cis- and trans-resveratrol in commercial wines. J. Wine Res. 6: 107-121.
44. Vrhovsek, U., Wendelin, S. and Eder, R. 1997. Effects of various vinification techniques on the concentration of cis- and trans-resveratrol and resveratrol glucoside isomers in wine. Am. J. Enol. Vitic. 48: 214-219. (Pubitemid 27266582)
45. Frémont, L. 2000. Biological effects of resveratrol. Life Sci. 66: 663-673.
46. Stervbo, U., Vang, O. and Bonnesen, C. 2007. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem. 101: 449-457. (Pubitemid 44333178)
47. LeBlanc, M. R. 2005. Cultivar, juice extraction, ultra violet irradiation and storage influence the stilbene content of muscadine grape (Vitis rotundifolia Michx.). Ph.D. Thesis, Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, USA.
48. Fritzemeier, K. H. and Kindl, H. 1981. Coordinate induction by UV light of stilbene synthase, phenylalanine ammonia-lyase and cinnamate 4-hydroxylase in leaves of vitaceae. Planta 151: 48-52.
49. Pedras, M. S. and Ahiahonu, P. W. 2005. Metabolism and detoxification of phytoalexins and analogs by phytopathogenic fungi. Phytochem. 66: 391-411. (Pubitemid 40215069)
50. Day, A. J., DuPont, M. S. and Ridley, S. et al. 1998. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS Lett. 436: 71-75. (Pubitemid 28454609)
51. Roldán, A., Palacios, V. and Caro, I. et al. 2003. Resveratrol content of Palomino fino grapes: influence of vintage and fungal infection. J. Agric. Food Chem. 51: 1464-1468.
52. Soleas, G. J., Diamandis, E. P. and Goldberg, D. M. 1997. Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal. 11: 287-313. (Pubitemid 27371787)
53. Iriti, M., Rossoni, M. and Borgo, M. et al. 2004. Benzothiadiazole enhances resveratrol and anthocyanin biosynthesis in grapevine, meanwhile improving resistance to Botrytis cinerea. J. Agric. Food Chem. 52: 4406-4413.
54. Romanazzi, G., Gabler, F. M. and Smilanick, J. L. 2006. Preharvest chitosan and postharvest UV irradiation treatments suppress gray mold of table grapes. Plant Disease 90: 445-450.
55. Guerrero, R. F., Puertas, B. and Fernández, M. I. et al. 2010. Induction of stilbenes in grapes by UV-C: Comparison of different subspecies of Vitis. Innovative Food Sci. Emerg. Technol. 11: 231-238.
56. Becker, J. V., Armstrong, G. O. and Van der Merwe, M. J. et al. 2003. Metabolic engineering of Saccharomyces cerevisiae for the synthesis of the wine-related antioxidant resveratrol. FEMS Yeast Res. 4: 79-85. (Pubitemid 38367534)
57. González-Candelas, L., Gil, J. V. and Lamuela-Raventós, R. M. et al. 2000. The use of transgenic yeasts expressing a gene encoding a glycosyl-hydrolase as a tool to increase resveratrol content in wine. Int. J. Food Microbiol. 59: 179-183. (Pubitemid 30628326)
58. Barreiro-Hurlé, J., Colombo, S. and Cantos-Villar, E. 2008. Is there a market for functional wines? Consumer preferences and willingness to pay for resveratrol-enriched red wine. Food Quality Prefer. 19: 360-371.
59. Poutaraud, A., Latouche, G. and Martins, S. et al. 2007. Fast and local assessment of stilbene content in grapevine leaf by in vivo fluorometry. J. Agric. Food Chem. 55: 4913-4920. (Pubitemid 47056035)
60. Hector, K. L., Lagisz, M. and Nakagawa, S. 2012. The effect of resveratrol on longevity across species: a meta-analysis. Biol. Lett. doi:10.1098/rsb1.2012.0316.
61. Güebailia, H. A., Chira, K. and Richard, T. et al. 2006. Hopeaphenol: the first resveratrol tetramer in wines from North Africa. J. Agric. Food Chem. 54: 9559-9564. (Pubitemid 46086119)
62. Ribeiro de Lima, M. T., Waffo-Teguo, P. and Teissedre, P. L. et al. 1999. Determination of stilbenes (trans-astringin, cis- and trans-piceid, and cis- and trans-resveratrol in Portuguese wines. J. Agric. Food Chem. 47: 2666-2670. (Pubitemid 29396336)
63. Vitrac, X., Bornet, A. and Vanderlinde, R. et al. 2005. Determination of stilbenes (δ-viniferin, trans-astringin, trans-piceid, cis- and trans-resveratrol, ε-viniferin) in Brazilian wines. J. Agric. Food Chem. 53: 5664-5669. (Pubitemid 41022461)
64. Pezet, R., Gindro, K. and Viret, O. et al. 2004. Glycosylation and oxidative dimerization of resveratrol are respectively associated to sensitivity and resistance of grapevine cultivars to downy mildew. Physiol. Molecul. Plant Pathol. 65: 297-303. (Pubitemid 40850031)
65. Soleas, G. J., Grass, L. and Josephy, D. P. et al. 2002. A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin. Biochem. 35: 119-124. (Pubitemid 34442691)
66. Wenzel, E. and Somoza, V. 2005. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49: 472-481. (Pubitemid 40780394)
67. Wenzel, E., Soldo, T. and Erbersdobler, H. et al. 2005. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 49: 482-494. (Pubitemid 40780395)
68. Renaud, S. C., Gueguen, R. and Siest, G. et al. 1999. Wine, beer, and mortality in middle-aged men from eastern France. Archiv. Intern. Med. 159: 1865-1870. (Pubitemid 29424706)
69. Vitaglione, P., Sforza, S. and Galaverna, G. et al. 2005. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 49: 495-504. (Pubitemid 40780396)
70. van Ginkel, P. R., Sareen, D. and Subramanian, L. et al. 2007. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin. Cancer Res. 13: 5162-5169. (Pubitemid 47502085)
71. Jannin, B., Menzel, M. and Berlot, J. P. et al. 2004. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: Plasmatic protein binding and cell uptake. Biochem. Pharmacol. 68: 1113-1118. (Pubitemid 39094275)
72. 3H]-trans-resveratrol in rat tissues following oral administration. Br. J. Nutr. 96: 62-70.
73. Bertelli, A. A. E., Giovannini, L. and Stradi, R. et al. 1996. Plasma, urine and tissue levels of trans-and cis-resveratrol (3′,4′, 5′-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int. J. Tissue React. 18: 67-71.
74. Frankel, E. N., Waterhouse, A. L. and Kinsella, J. E. 1993. Inhibition of human LDL oxidation by resveratrol. Lancet 341: 1103-1104. (Pubitemid 23114451)
75. De Lédinghen, V., Monvoisin, A. and Neaud, V. et al. 2001. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int. J. Oncol. 19: 83-88.
76. De Santi, C., Pietrabissa, A. and Spisni, R. et al. 2000. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30: 609-617. (Pubitemid 30449570)
77. Walle, T., Hsieh, F. and DeLegge, M. H. et al. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabol. Dispos. 32: 1377-1382. (Pubitemid 39564557)
78. Marier, J. F., Vachon, P. and Gritsas, A. et al. 2002. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302: 369-373. (Pubitemid 34680460)
79. Tsan, M. F., White, J. E. and Maheshwari, J. G. et al. 2000. Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. Br. J. Haematol. 109: 405-412. (Pubitemid 30350725)
80. Urpi-Sarda, M., Jáuregui, O. and Lamuela-Raventos, R. M. et al. 2005. Uptake of diet resveratrol into the human low-density lipoprotein identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem. 77: 3149-3155.
81. Chen, Y., Tseng, S. H. and Lai, H. S. et al. 2004. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery. 136: 57-66. (Pubitemid 38834220)
82. Bertelli, A. A. E. 2007. Wine, research and cardiovascular disease: Instructions for use. Atherosclerosis 195: 242-247. (Pubitemid 350087967)
83. Bertelli, A., Bertelli, A. A. E. and Gozzini, A. et al. 1998. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp. Clin. Res. 24: 133-138. (Pubitemid 28499568)
84. Mertens-Talcott, S. U. and Percival, S. S. 2005. Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett. 218: 141-151. (Pubitemid 40164715)
85. Chan, M. M., Mattiacci, J. A. and Hwang, H. S. et al. 2000. Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. Biochem. Pharmacol. 60: 1539-1548.
86. Fang, J. G., Lu, M. and Chen, Z. H. et al. 2002. Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chem. 8: 4191-4198.
87. Conte, A., Pellegrini, S. and Tagliazucchi, D. 2003. Synergistic protection of PC12 cells from β-amyloid toxicity by resveratrol and catechin. Brain Res. Bull. 62: 29-38. (Pubitemid 37330112)
88. Heredia, A., Davis, C. and Redfield, R. 2000. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J. Acquir. Immune Defic. Syndr. 25: 246-255. (Pubitemid 32010127)
89. Vivancos, M. and Moreno, J. J. 2008. Effect of resveratrol, tyrosol and β-sitosterol on oxidized low-density lipoprotein-stimulated oxidative stress, arachidonic acid release and prostaglandin E2 synthesis by RAW 264.7 macrophages. Br. J. Nutr. 99: 1199-1207.
90. Goldberg, D. M., Yan, J. and Soleas, G. J. 2003. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36: 79-87. (Pubitemid 36126394)
91. Juan, M. E., Vinardell, M. P. and Planas, J. M. 2002. The daily oral administration, of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132: 257-260. (Pubitemid 34135604)
92. Williams, L. D., Burdock, G. A. and Edwards, J. A. et al. 2009. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem. Toxicol. 47: 2170-2182.
93. Arthur, P. G., Niu, X. and Rigby, P. et al. 2008. Oxidative stress causes a decline in lysosomal integrity during hypothermic incubation of rat hepatocytes. Free Radical Biol. Med. 44: 24-33. (Pubitemid 350138625)
94. Holvoet, P. 2004. Oxidized LDL and coronary heart disease. Acta Cardiol. 59: 479-484. (Pubitemid 39331216)
95. Li, Y., Cao, Z. and Zhu, H. 2006. Up-regulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol. Res. 53: 6-15. (Pubitemid 41619373)
96. Wenzel, E., Soldo, T. and Erbersdobler, H. et al. 2005. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 49: 482-494. (Pubitemid 40780395)
97. Whitehead, T. P., Robinson, D. and Allaway, S. et al. 1995. Effect of red wine ingestion on the antioxidant capacity of serum. Clin. Chem. 41: 32-35.
98. Baur, J. A., Pearson, K. J. and Price, N. L. et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342. (Pubitemid 44764104)
99. Howitz, K. T., Bitterman, K. J. and Cohen, H. Y. et al. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196. (Pubitemid 37150899)
100. Valenzano, D. R., Terzibasi, E. and Genade, T. et al. 2006. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-rlived vertebrate. Curr. Biol. 16: 296-300. (Pubitemid 43190229)
101. Wood, J. G., Rogina, B. and Lavu, S. et al. 2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689. (Pubitemid 39061685)
102. Jang, M. S., Cai, E. N. and Udeani, G. O. et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Sci. 275: 218-220. (Pubitemid 127696281)
103. Aggarwal, B., Bhardwaj, A. and Aggarwal, R. S. et al. 2004. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 24: 2783-2840. (Pubitemid 39409568)
104. Schneider, Y., Duranton, B. and Gosse, F. et al. 2001. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr. Cancer. 39: 102-107. (Pubitemid 32880955)
105. Garvin, S., Ollinger, K. and Dabrosin, C. 2006. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231: 113-122. (Pubitemid 41779459)
106. Trincheri, N. F., Nicotra, G. and Follo, C. et al. 2007. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 28: 922-931. (Pubitemid 47072174)
107. Bhardwaj, A., Sethi, G. and Vadhan-Raj, S. et al. 2007. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor kB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302. (Pubitemid 46425866)
108. Sun, C., Hu, Y. and Liu, X. et al. 2006. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet. Cytogen. 165: 9-19. (Pubitemid 43254647)
109. Busquets, S., AmEtller, E. and Fuster, G. et al. 2007. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 245: 144-148.
110. Benitez, D. A., Pozo-Guisado, E. and Alvarez-Barrientos, A. et al. 2007. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostrate cancer-derived cell lines. J. Androl. 28: 282-293. (Pubitemid 46423911)
111. Hwang, J. T., Kwak, D. W. and Lin, S. K. et al. 2007. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signalling pathway. Ann. N.Y. Acad. Sci. 1095: 441-448.
112. Cecchinato, V., Chiaramonte, R. and Nizzardo, M. et al. 2007. Resveratrol induced apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. Biochem. Pharmacol. 74: 1568-1574. (Pubitemid 47614962)
113. Su, J. L., Yang, C. Y. and Zhao, M. et al. 2007. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J. Biol. Chem. 282: 19385-19398. (Pubitemid 47100112)
114. Burgering, B. M. and Kops, G. J. 2002. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27: 352-360. (Pubitemid 34756518)
115. Shankar, S., Siddiqui, I. and Srivastava, R. K. 2007. Molecular mechanisms of resveratrol (3′,4′,5′-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostrate cancer cells. Mol. Cell Biochem. 304: 273-285. (Pubitemid 47456876)
116. Harper, C. E., Patel, B. B. and Wang, J. et al. 2007. Resveratrol suppresses prostrate cancer progression in transgenic mice. Carcinogenesis 28: 1946-1953. (Pubitemid 47500607)
117. Garvin, S., Ollinger, K. and Dabrosin, C. 2006. Resveratrol induces apoptosis and angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231: 113-122. (Pubitemid 41779459)
118. Stocco, B., Toledoa, K. and Salvador, M. et al. 2012. Dose-dependent effect of Resveratrol on bladder cancer cells: Chemoprevention and oxidative stress. Maturitasx 72: 72-78.
119. Provinciali, M., Re, F., Donnini, A. and Orlando, F. et al. 2005. Effect of resveratrol on the development of spontaneous mammary tumours in HER-2/neu transgenic mice. Int. J. Cancer 115: 36-45. (Pubitemid 40559666)
120. La Vecchia, C. and Bosetti, C. 2006. Diet and cancer risk in Mediterranean countries: open issues. Public Health Nutr. 9: 1077-1082.
121. Golkar, L., Ding, X. Z. and Ujiki, M. B. et al. 2007. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J. Surg. Res. 138: 163-169. (Pubitemid 46365718)
122. Sexton, E., Themsche, C. V. and Leblanc, K. et al. 2006. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. Cancer 5: 45.
123. Harikumar, K. B., Kunnumakkara, A. B. and Sethi, G. et al. 2010. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer. 127: 257-268.
124. Wu, S. L., Sun, Z. J. and Yu, L. et al. 2004. Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J. Gastroenterol. 10: 3048-3052. (Pubitemid 39303061)
125. Bernhaus, A., Ozsvar-Kozma, M. and Saiko, P. et al. 2009. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest. New Drugs 27: 393-401.
126. Hurst, S., Loi, C. M. and Brodfuehrer, J. et al. 2007. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin. Drug Metab. Toxicol. 3: 469-489. (Pubitemid 351324958)
127. Chan, O. H. and Stewart, B. H. 1996. Physicochemical and drug delivery considerations for oral drug bioavailability. Drug Discov. Today 1: 461-473. (Pubitemid 126393548)
128. Nam, J. B., Ryu, J. H. and Kim, J. W. et al. 2005. Stabilization of resveratrol immobilized in monodisperse cyano-functionalized porous polymeric microspheres. Polymer 46: 8956-8963.
129. Shi, G., Rao, L. and Yu, H. et al. 2008. Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int. J. Pharm. 349: 83-93. (Pubitemid 350299698)
130. López-Nicolás, J. M., Núñez-Delicado, E. and Pérez-López, A. J. et al. 2006. Determination of stoichiometric coefficients and apparent formation constants for β-cyclodextrin complexes of trans-resveratrol using reversed-phase liquid chromatography. J. Chromatogr. A 1135: 158-165. (Pubitemid 44692693)
131. Lucas-Abellán, C., Fortea, I. and López-Nicolás, J. M. et al. 2007. Cyclodextrins as resveratrol carrier system, Food Chem. 104: 39-44. (Pubitemid 46562545)
132. Lu, Z., Cheng, B. and Hu, Y. et al. 2009. Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity. Food Chem. 113: 17-20.
133. Das, S., Lin, H. S. and Ho, P. C. et al. 2008. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm. Res. 25: 2593-2600.
134. Li, D. C., Zhong, X. K. and Zeng, Z. P. et al. 2009. Application of targeted drug delivery system in Chinese medicine. J. Control. Release 138: 103-112.
135. Atanacković, M., Posa, M. and Heinle, H. et al. 2009. Solubilization of resveratrol in micellar solutions of different bile acids. Colloids Surf. B 72: 148-154.
136. Ndiaye, M., Kumar, R. and Ahmad, N. 2011. Resveratrol in cancer management: where are we and where we go from here? Ann. N. Y. Acad. Sci. 1215: 144-149.
137. Johnson, J. J., Nihal, M. and Siddiqui, I. A. et al. 2011. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 55: 1169-1176.
138. Kapetanovic, I. M., Muzzio, M. and Huang, Z. et al. 2011. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 68: 593-601.
139. Youn, J., Lee, J. S. and Na, H. K. et al. 2009. Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. Nutr. Cancer 61: 847-854.
140. Cottart, C. H., Nivet-Antoine, V. and Laguillier-Morizot, C. et al. 2010. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 54: 7-16.
141. Boocock, D. J., Faust, G. E. and Patel, K. R. et al. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16: 1246-1252. (Pubitemid 46984966)
142. Almeida, L., Vaz-da-Silva, M. and Falcão, A. et al. 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53: S7-S15.